Mª ÁNGELES SOLINIS ASPIAZU-rekin lankidetzan egindako argitalpenak (27)

2024

  1. Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893

  2. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach

    Antibiotics, Vol. 13, Núm. 6

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  2. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?

    Pharmaceutics, Vol. 15, Núm. 4

2022

  1. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71

  2. Oral calcium fosfomycin: Pharmacokinetic/pharmacodynamic study

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 76-78

  3. Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate compared to linezolid for the treatment of infections caused by gram-positive bacteria

    Antibiotics, Vol. 10, Núm. 7

  4. Pharmacokinetic/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 10, pp. 2145-2152

  5. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  6. Pseudomonas aeruginosa susceptibility in spain: Antimicrobial activity and resistance suppression evaluation by pk/pd analysis

    Pharmaceutics, Vol. 13, Núm. 11

  7. Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies

    Pharmaceutics, Vol. 13, Núm. 7

  8. α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

    Pharmaceutics, Vol. 13, Núm. 6

2019

  1. Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 121-129

  2. Efectividad de las medidas de atención farmacéutica para la deprescripción de benzodiazepinas y análogos en atención primaria

    Congreso Nacional de Atención Farmacéutica (11º. Cádiz. 2019)

  3. Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 380-386

  4. Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 626-633

2018

  1. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review

    Clinical Pharmacokinetics, Vol. 57, Núm. 9, pp. 1107-1121

2015

  1. Impacto de las acciones de mejora para el control farmacoterapéutico de la insuficiencia cardíaca en atención primaria

    Congreso Nacional de Atención Farmacéutica (9º. Toledo. 2015)